Spyre Therapeutics, Inc. (SYRE) Institutional Ownership

Ownership Summary

Spyre Therapeutics, Inc. (NASDAQ:SYRE) has 151 institutional investors that have filed 13F reports for the period ending December 2025.

• These investors held 131.2% of outstanding shares in December 2025, up from 107.5% in September 2025.
• They increased total shares held in Spyre Therapeutics by 27.82% from last quarter, and the number of investors in SYRE increased 16.15% annually.
• Among the 151 funds, 104 bought more Spyre Therapeutics shares, 27 sold down, and 20 held their ground.
• Institutional investors collectively held 79.28Mn shares in Spyre Therapeutics as of December 2025, up by 17.26Mn shares quarter on quarter, and up 17.86Mn shares year over year.
• As of December 31, 2025, the biggest holder of Spyre Therapeutics is FMR LLC at 11.78Mn shares, representing 19.5% of shares outstanding.
• The biggest buyers of Spyre Therapeutics for the quarter ending December 2025 included VANGUARD CAPITAL MANAGEMENT LLC (3.06Mn), PRICE T ROWE ASSOCIATES INC /MD/ (1.6Mn), Janus Henderson Group Plc (1.48Mn), Jpmorgan Chase & Co (916.35K), Caligan Partners LP (878.13K).
• The largest sales of SYRE for the quarter ending December 2025 came from Capital International Investors (1.75Mn), BRAIDWELL LP (701.79K), Commodore Capital LP (475.86K), Pictet Asset Management Holding SA (422.31K), Goldman Sachs Group Inc (280.19K).
• According to Business Quant data, leading holders of SYRE for December 2025 are FMR LLC (11.78Mn), BlackRock, Inc. (5.52Mn), RTW INVESTMENTS, LP (4.17Mn), Fairmount Funds Management LLC (4.02Mn), PERCEPTIVE ADVISORS LLC (3.78Mn), Venrock Adviser, LLC (3.69Mn), Janus Henderson Group Plc (3.31Mn), VANGUARD CAPITAL MANAGEMENT LLC (3.06Mn), DRIEHAUS CAPITAL MANAGEMENT LLC (2.79Mn), State Street Corp (2.61Mn).